3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Fluorouracil
41
Radiotherapy
38
Cisplatin
35
Oxaliplatin
32
Leucovorin
24
Paclitaxel
22
Irinotecan
20
Docetaxel
17
Neoadjuvant Therapy
14
Carboplatin
13
Radiation
12
Capecitabine
12
Surgical Procedures, Operative
10
Cetuximab
8
Biopsy
8
durvalumab
7
Gefitinib
7
Chemotherapy, Adjuvant
7
tremelimumab
6
pembrolizumab
6
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Folfox protocol
6
Taxes
5
Immunohistochemistry
5
Endoscopy
5
Gene Expression Profiling
4
Epirubicin
4
Drug Therapy
4
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma Of Esophagus
×
High-Intensity Interval Training
×
Clear all
NCT07375420
2026-02-02
OPTIMUS
University of Surrey
Phase NA
Recruiting
50 enrolled